33.39
+11.97%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Schrodinger
From its filings with the US Securities and Exchange Commission
Schrodinger is based in New York, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SDGR. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $255.9m and a net loss of $103.3m. At that date it held total assets of $726.2m and shareholders' equity of $364.1m. By region, United States accounted for 59.8%, followed by EMEA at 29.4% and APAC at 10.2%.
Our differentiated, physics-based computational platform enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at a lower cost, compared to traditional methods. Our software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. We are applying our computational platform to advance a broad pipeline of drug discovery programs in collaboration with leading biopharmaceutical companies. In addition, we use our computational platform to discover novel molecules for our pipeline of proprietary drug discovery programs, which we are advancing through preclinical and clinical development.
Traditional drug discovery and development efforts are complex, lengthy and capital-intensive, and are prone to high failure rates. Traditional drug discovery relies upon many iterations of costly and time-consuming manual molecule design, chemical synthesis, and experimental testing. One of the primary reasons for long timelines, high costs, and high failure rates in drug discovery is that predicting properties of molecules in advance of chemical synthesis is extremely complex and not amenable to traditional approaches.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Technology
- Listed since
- 6 Feb 2020
- Employees
- 850
- Website
- schrodinger.com ↗
- Head office
- 1540 BROADWAY, NEW YORK, NY, 10036
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Michael LyntonIndependent Chairman of the Board$300,425
- Dr. Ramy FaridPresident, Chief Executive Officer, Director, since 2008$4.4m
- Mr. Richie JainExecutive Vice President, Chief Financial Officer, Treasurer
- Dr. Karen AkinsanyaPresident - R&D Therapeutics$2.7m
- Ms. Yvonne TranChief People Officer, Executive Vice President, Chief Legal Officer$1.5m
- Dr. Robert AbelExecutive Vice President, Chief Scientific Officer, Platform$2.1m
- Mr. Mannix AklianExecutive Vice President, Chief Commercial Officer, Global Head of Software Sales & Marketing
- Mr. Kenneth LortonExecutive Vice President, Chief Operating Officer - Software$2.1m
- Ms. Margaret DuganChief Medical Officer$3.2m
- Dr. Richard FriesnerDirector$668,825
- Dr. Jeffrey ChodakewitzIndependent Director$260,425
- Mr. Gary GinsbergIndependent Director$257,925
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 63
- Environment
- 32
- Social
- 79
- Governance
- 77
- Direct emissions (scope 1)
- 249 t
- Energy emissions (scope 2)
- 901 t
- Value chain emissions (scope 3)
- 31,431 t
- Women in the workforce
- 32.5%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Schrodinger Inc possesses several strengths that contribute to its success and market position. These include:
Weaknesses
- Despite its strengths, Schrodinger Inc also faces some weaknesses that need to be addressed in order to maintain its competitive edge:
Opportunities
- Several opportunities exist for Schrodinger Inc to further expand and enhance its business:
Threats
- Schrodinger Inc should also be aware of the following threats that may pose challenges to its success:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.